BACKGROUND: Cyclin G2 is a novel cyclin negatively regulating the cell cycle progression, contrary to the characteristics of conventional cyclins. However, little is known about the cyclin G2 expression in human carcinomas. We thus investigated cyclin G2 expression in human thyroid neoplasms. MATERIALS AND METHODS: We immunohistochemically examined cyclin G2 expression in 40 normal thyroids and 80 thyroid neoplasms. RESULTS: Normal thyroids expressed cyclin G2 in more than 5% of follicular cells. Of 30 papillary carcinomas including 6 microcarcinoma, cyclin G2 expression was not, or only occasionally, observed in carcinoma cells, indicating its expression decreased in all these cases. On the other hand, in 16 of the 24 follicular adenomas (66.7%) and 5 of the 23 follicular carcinomas (21.7%), cyclin G2 expression was retained (more than 5% of neoplastic cells were positive), and adenomas more frequently (p = 0.0032) retained cyclin G2 expression than carcinomas. CONCLUSION: Our results suggest that lack of cyclin G2 plays an important role in the malignant transformation of papillary carcinoma. Also, it may play an adjuvant role in the transformation of follicular adenoma to carcinoma. This is the first study of the expression of cyclin G2, a novel cyclin having a role opposite to that of conventional cyclins, in human carcinoma.
BACKGROUND:Cyclin G2 is a novel cyclin negatively regulating the cell cycle progression, contrary to the characteristics of conventional cyclins. However, little is known about the cyclin G2 expression in humancarcinomas. We thus investigated cyclin G2 expression in humanthyroid neoplasms. MATERIALS AND METHODS: We immunohistochemically examined cyclin G2 expression in 40 normal thyroids and 80 thyroid neoplasms. RESULTS: Normal thyroids expressed cyclin G2 in more than 5% of follicular cells. Of 30 papillary carcinomas including 6 microcarcinoma, cyclin G2 expression was not, or only occasionally, observed in carcinoma cells, indicating its expression decreased in all these cases. On the other hand, in 16 of the 24 follicular adenomas (66.7%) and 5 of the 23 follicular carcinomas (21.7%), cyclin G2 expression was retained (more than 5% of neoplastic cells were positive), and adenomas more frequently (p = 0.0032) retained cyclin G2 expression than carcinomas. CONCLUSION: Our results suggest that lack of cyclin G2 plays an important role in the malignant transformation of papillary carcinoma. Also, it may play an adjuvant role in the transformation of follicular adenoma to carcinoma. This is the first study of the expression of cyclin G2, a novel cyclin having a role opposite to that of conventional cyclins, in humancarcinoma.
Authors: Aruni S Arachchige Don; Robert F Dallapiazza; David A Bennin; Tiffany Brake; Colleen E Cowan; Mary C Horne Journal: Exp Cell Res Date: 2006-09-29 Impact factor: 3.905
Authors: L Mourgues; V Imbert; M Nebout; P Colosetti; Z Neffati; P Lagadec; E Verhoeyen; C Peng; E Duprez; L Legros; N Rochet; V Maguer-Satta; F-E Nicolini; D Mary; J-F Peyron Journal: Leukemia Date: 2015-04-30 Impact factor: 11.528
Authors: Maike Zimmermann; Aruni P S Arachchige-Don; Michaela S Donaldson; Tommaso Patriarchi; Mary C Horne Journal: Cell Cycle Date: 2016-10-18 Impact factor: 4.534
Authors: Maike Zimmermann; Aruni S Arachchige-Don; Michaela S Donaldson; Robert F Dallapiazza; Colleen E Cowan; Mary C Horne Journal: J Biol Chem Date: 2012-05-15 Impact factor: 5.157